7 news items
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
and next-generation therapies, leveraging our innovative, decentralized cell therapy manufacturing platform. For patients with head & neck cancer
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
and next-generation therapies, leveraging our innovative, decentralized cell therapy manufacturing platform. For patients with head & neck cancer
Galapagos And Blood Centers Of America Collaborate To Expand Galapagos' Decentralized CAR-T Manufacturing Network In The U.S.
GLPG
15 May 24
role by supporting site initiation and onboarding to accelerate Galapagos' efforts and ensure consistent quality.Galapagos' innovative
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
GLPG
15 May 24
. Galapagos' innovative, decentralized manufacturing platform could address many of the limitations that currently available CAR-T production is facing
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
with a renewed focus, a differentiated and expanding R&D pipeline, and competitive technology platforms to bring innovation to patients around
n4rc1rfwlcuzr6iumzqvjm2rs6x1uvpbq90m6 i2b3kmrn3sxhejgx6
GLPG
4 Apr 24
. "We are committed to accelerating breakthrough innovations to extend the reach of CAR-T therapies to patients with rapidly progressing cancers," said
zi3107av45yxmsldwo5 n1l0f8n0jp9cfo6m
GLPG
26 Mar 24
forward to working with the team and to contributing to the company's mission of pioneering on behalf of patients and accelerating innovation
- Prev
- 1
- Next